Aviragen Therapeutics (AVIR) Tops Q1 EPS by 2c
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $570 thousand.
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald's (MCD) Tops Q4 EPS by 3c
- Barclays Upgrades Essex Property Trust (ESS) to Overweight
- UPDATE: Wells Fargo Downgrades Verizon Communications (VZ) to Market Perform
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!